Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy.

BACKGROUND AND PURPOSE To correlate acute esophageal toxicity with dosimetric and clinical parameters for non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT) alone or with chemo-radiotherapy (CRT). PATIENTS AND METHODS We analyzed the data of 156 patients with medically inoperable or locally advanced NSCLC. Seventy-four patients were irradiated with high dose RT only, 45 patients with sequential CRT (Gemicitabine/Cisplatin) and 37 patients with concurrent CRT (Cisplatin daily 6 mg/m(2)). The radiation dose delivered ranged from 49.5 to 94.5 Gy (2.25-2.75 Gy per fraction) with an overall treatment time of 5-6 weeks. For all patients the maximal acute esophageal toxicity (RTOG/EORTC criteria) was scored and related to dose-volume parameters, as well as to clinical and treatment-related parameters. All parameters were tested univariable and multivariable in a binary logistic regression model. The toxicity data of a homogeneous subgroup was fitted to the Lyman-Kutcher-Burman model. RESULTS Grade 2 acute esophageal toxicity or higher occurred in 27% (n=42) of the patient population of which nine patients developed grade 3 toxicity and one patient grade 4. All 10 patients with grade>or=3 esophageal toxicity received concurrent CRT. At multivariable analysis, the most significant clinical parameter to predict acute esophageal toxicity was the concurrent use of CRT. The most significant dosimetric parameter was the esophagus volume that received at least 35 Gy. The data of the patients who did not receive concurrent CRT were well described by the Lyman-Kutcher-Burman normal tissue complication probability model. The optimal fit of the data of non-concurrent treated patients to this model was obtained using the following values for the parameters: TD(50)=47 Gy (41-60 Gy), n=0.69 (0.18-6.3) and m=0.36 (0.25-0.55) where the numbers between brackets denote the 95% confidence interval. Acute esophageal toxicity was not significantly increased for patients treated with sequential CRT. CONCLUSION Both concurrent CRT and the volume that receives at least 35 Gy were predictors of acute esophageal toxicity.

[1]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  José Belderbos,et al.  Biology contributionComparing different NTCP models that predict the incidence of radiation pneumonitis , 2003 .

[3]  Mischa S. Hoogeman,et al.  The design and implementation of a multi-center volumetric and dosimetric database , 2000 .

[4]  P. Maguire,et al.  Clinical and dosimetric predictors of radiation-induced esophageal toxicity. , 1999, International journal of radiation oncology, biology, physics.

[5]  T. Bortfeld,et al.  The use of computers in radiation therapy : XIIIth International Conference Heidelberg, Germany, May 22-25, 2000 , 2000 .

[6]  P Baas,et al.  Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Joos V Lebesque,et al.  Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. , 2003, International journal of radiation oncology, biology, physics.

[8]  Icru Prescribing, recording, and reporting photon beam therapy , 1993 .

[9]  R K Ten Haken,et al.  Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Burman,et al.  Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. , 1989, International journal of radiation oncology, biology, physics.

[11]  M. Satouchi,et al.  Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[12]  R. Komaki,et al.  Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. , 1998, International journal of radiation oncology, biology, physics.

[13]  P. van Luijk,et al.  Estimation of parameters of dose-volume models and their confidence limits. , 2003, Physics in medicine and biology.

[14]  H. Bartelink,et al.  Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer. , 2000, European journal of cancer.

[15]  M. V. van Herk,et al.  Quantification of local rectal wall displacements by virtual rectum unfolding. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  J. Lyman Complication probability as assessed from dose-volume histograms. , 1985, Radiation research. Supplement.

[17]  W. Curran,et al.  Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. , 2001, Chest.

[18]  H. Fukuda,et al.  European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .

[19]  H. Choy,et al.  Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. , 1999, Seminars in radiation oncology.

[20]  Issam El-Naqa,et al.  Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. , 2004, International journal of radiation oncology, biology, physics.

[21]  R Mohan,et al.  Clinically relevant optimization of 3-D conformal treatments. , 1992, Medical physics.

[22]  L. Boersma,et al.  First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  J. Lebesque,et al.  The simultaneous boost technique: the concept of relative normalized total dose. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  Jeffrey D Bradley,et al.  Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[25]  W. Curran,et al.  Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. , 2000, International journal of radiation oncology, biology, physics.

[26]  M. Socinski,et al.  High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. , 2002, International journal of radiation oncology, biology, physics.

[27]  J. Lebesque,et al.  A treatment planning method to correct dose distributions distorted by setup verification fields. , 2000, International journal of radiation oncology, biology, physics.

[28]  Target dose inhomogeneity and the location of recurrence , 2002 .

[29]  A Ottolenghi,et al.  Radiation pneumonitis after breast cancer irradiation: analysis of the complication probability using the relative seriality model. , 2000, International journal of radiation oncology, biology, physics.